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Purpose: The identiﬁcation of variables associated with health-related quality of life (HRQoL) in patients with
mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS) would improve surgical decision-
making and post-operatory follow-up in this group of patients.
Methods: We analyzed the independent association between the Quality of Life in Epilepsy Inventory—31
(QOLIE-31) of 81 consecutive patients with refractory MTLE-HS. The clinical, demographic, radiological and
electrophysiological variables were analyzed by multiple linear regression analysis.
Key ﬁndings:Approximately 36% (adjusted R2=0.36; R coefﬁcient=0.66) of the QOLIE-31 overall score variance
was explained by the history of initial precipitant injury, family history of epilepsy, disease duration, age of
epilepsy onset, seizure frequency and presence of psychiatric axis-II diagnosis. The variance of QOLIE‐31 sub-
scales was: seizure worry=7%; overall QOL=11%; emotional well‐being=32%; energy/fatigue=38%; cogni-
tive function=13%; medication effects=7%; social function=13% (R coefﬁcient between 0.30 and 0.65).
Signiﬁcance: The pre-surgical variables studied had relatively low prediction capacity for the overall QOLIE-31
score and its sub-scales in this set of Brazilian patients with refractory MTLE‐HS.© 2012 Elsevier Inc.Open access under the Elsevier OA license. 1. Introduction
Epilepsy has been associated with poor health‐related quality of life
(HRQoL) worldwide [1–6]. In most studies assessing HRQoL, patients
have been surveyed regarding their syndromic diagnosis, duration and
severity of the disease, type of treatment, and social and cultural fea-
tures. Though useful for epidemiologic purposes, this approach provides
limited information regarding treatment strategy of selected popula-
tions or decision-making in individual cases.
Prognostic models using multivariate analysis are statistical models
that combine two or more variables of patient's data to predict clinical
outcome [7]. Multivariate analysis may be particularly useful to predict
HRQoL in patients with epilepsy [3,4], controlling for the several sourcesédica, Hospital Universitário, 3
, CEP 88.040‐970 Florianópolis,
OA license. of potential confounding bias that may interfere with interpretation of
the ﬁnal scores of instruments for HRQoL determination [4].
Management of epilepsy is directed towards restoring HRQoL to
acceptable levels [3]. Over the years, good seizure control with low side
effects has been recognized as an important aspect of HRQoL. More re-
cently, psychosocial variables, in particular, psychiatric symptoms
[2,4,8,9], have gained more attention from epileptologists and neurolo-
gists [3,4,10] because of the increasing recognition of their role in HRQoL.
Twenty percent of patients with epilepsy have seizures that are
medically intractable, and mesial temporal lobe epilepsy related to hip-
pocampal sclerosis (MTLE-HS) is the most common form of surgically
remediable epileptic syndrome [11,12]. The clinical, radiological, elec-
trophysiological, psychiatric, neuropsychological and neuropathologi-
cal characteristics of this syndrome have been relatively well deﬁned,
but independent determinants of HRQoL of these patients remain to
be identiﬁed. Better understanding of pre-surgical HRQoL determinants
in patientswith refractoryMTLE-HSmay provide important insight into
the prognosis, inﬂuencing decision-making and post-operative follow‐
up. Here, we investigated the independent association between
presurgical variables and the total score of the Quality of Life in Epilepsy
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subscales composing the QOLIE-31.
2. Methods
2.1. Patients
Eighty-one adult consecutive patients with refractory MTLE-HS
were enrolled. All underwent pre-surgical evaluation at the Centro
de Epilepsia de Santa Catarina (CEPESC) between October 2008 and
December 2011.
Refractoriness was deﬁned as failure to respond to at least 2 anti-
epileptic drugs in adequate trials [13], with patients showing seizures
impairing awareness occurring at least once a month.
All patients had complete medical history, seizure semiology, neuro-
logical examination, psychiatric and neuropsychological evaluation,
interictal and ictal video-EEG analyses, and MRI results consistent with
MTLE-HS [14–19].
The clinical picture consisted of complex partial seizures with epi-
gastric, autonomic, or psychic auras; focal slowing, interictal spikes,
and sharpwaves over the anterior, inferior, andmesial temporal regions
on interictal scalp EEG; and hippocampal atrophy on T1 and increased
hippocampal signal on T2 MRI sequences. We also included patients
without an aura, with normal routine EEGs or bilateral interictal spikes,
or with bilateral hippocampal atrophy on MRI.
Histopathology conﬁrmed hippocampus sclerosis in 48 surgically
treated patients. We excluded patients with extrahippocampal lesions,
focal motor-sensory abnormalities on physical examination, general-
ized or extratemporal interictal spikes and marked cognitive impair-
ment on neuropsychological testing because such features place the
diagnosis ofMTLE in doubt [14–19]. Patients presentingwith acute psy-
chotic symptoms during evaluation were also excluded from the study.
The clinical characteristics analyzed were sex, age, age of epilepsy
onset (recurrent seizures), duration of epilepsy, years of education, pos-
itive history for an initial precipitant injury (IPI), epilepsy duration until
the pre-surgical evaluation, positive family history of seizures in ﬁrst-
degree relatives, monthly complex partial seizure frequency impairing
awareness in the year before the cognitive evaluation, and side ofmesial
temporal abnormality. Patients were considered to be under mono-
therapy if they were using only one AED. Patients using one AED
and benzodiazepines (BDZs) were classiﬁed in the group of mono-
therapy plus BDZs. Patients using two or more AEDs, associated or not
with BDZs, were classiﬁed as being under polytherapy. The AEDs used
were phenytoin, carbamazepine, phenobarbital, or valproate. The BDZs
used were clobazam or clonazepam. The video-EEG (VEEG) recording
(Bio-logic, System Corp.) was done using scalp electrodes according to
the international 10/20 system associated with temporal 10/10 system.
Visual interictal analysis was assessed in a one-hour sleep sample (be-
tween 5:00 and 7:00 a.m.) and one-hour sample during wakefulness
(between 8:00 and 10:00 a.m.) in the ﬁrst, second and third days of
VEEG monitoring. The patients had a mean of 4 seizures (±2.5) during
the investigation. The local Research Ethics Committee approved the
study, and informed consent was obtained from all patients.
2.2. Psychiatric evaluation
All patientswere assessed by an experienced psychiatristwith exper-
tise in psychiatric comorbidities associated with epilepsy (RG) as previ-
ously described [14,20]. The psychiatric interviews were blind for QOL
and lasted for about 90 to 120 minutes. All patients were interviewed
alone and thereafter along with the caregiver. Present (current) and
past (lifetime) axis I disorders were diagnosed according to the Struc-
tured Clinical Interview for Diagnostic and Statistical Manual of Mental
Disorders 4th edition – DSM-IV – Axis I Disorders, Clinical Version
(SCID I) [21,22]. All the diagnoses were re-allocated into three main
groups: 1) depressive disorders; 2) anxiety disorders; and 3) psychoticdisorders. In addition,we also considered three psychiatric comorbidities
speciﬁcally associated with epilepsy as described by the ILAE Commis-
sion on Psychobiology: interictal dysphoric disorder (IDD); postictal psy-
chosis (PIP); and interictal psychosis (IIP) [24]. Interictal dysphoric
disorderwas allocated into the depressive disorders group. Postictal psy-
chosis and IIP were allocated into the psychotic disorders group. Axis II
Personality Disorders (PD) were classiﬁed according to the DSM-IV
[23].We also have considered a speciﬁc Axis II PD associatedwith epilep-
sy, termed the Gastaut–Geschwind syndrome (GGS) [24], which was
classiﬁed as “other personality disorders” into Axis II from DSM-IV.
The patients were allocated into the following major diagnostic
groups: current axis I: 0=no diagnosis; 1=anxiety disorders; 2=
depressive disorders. Past axis I: 0=no diagnosis; 1=anxiety disor-
ders; 2=depressive disorders; 3=psychotic disorders. According to
axis II, the diagnosis of the patients was deﬁned as: 0=no diagnosis;
1=personality disorders.
2.3. Quality‐of‐life evaluation
Quality of lifewas assessed during the pre-surgical evaluationwith a
Brazilian version of QOLIE-31 that shows a good reliability, validity, and
construct validity [1]. The QOLIE-31 is a widely adopted epilepsy-
speciﬁc QOL instrument [25]. It comprises 30 items divided into seven
subscale domains: seizure worry (5 items); emotional well-being (5
items); energy/fatigue (4 items); cognitive functioning (6 items); med-
ication effects (3 items); overall quality of life (2 items) and social func-
tion (5 items). Each domainwas scored by calculating themean score of
responses within that domain. The raw scores were converted to “0 to
100”, with higher scores reﬂecting better QOL. Total and subscale scores
were calculated according to the QOLIE-31 scoring manual [5].
2.4. Statistical analysis
A univariate analysis was done to investigate the association
between the patients' overall QOLIE-31 scores as well as each of the
seven subscale domains (dependent variables) and their clinical, de-
mographic, neuroradiologic, and psychiatric variables (independent
variables). The differences between the QOLIE‐31 scores and the categor-
ical variableswere determined byMann–Whitney test or Kruskall–Wallis
test due to the relatively high asymmetry of the sample sizes in the cate-
gories. Because the QOLIE-31 score and the subscale domains showed a
normal distribution (Kolmogorov–Smirnov test), their association with
the independent clinical, demographic, neuroradiologic, and psychiatric
variables was investigated by linear regression. The independent vari-
ables that showed an association with the QOLIE‐31 score and the
subscale domains (dependent variables) in the univariate analysis with
a “p” level of signiﬁcance lower than 0.20were included in amultiple lin-
ear regression analysis. This analysis was done to identify the clinical, de-
mographic, neuroradiologic, and psychiatric variables that could be
considered as good predictors for the overall QOLIE-31 as well as each
of the seven subscale domains. In this analysis, the independent continu-
ous variables were considered covariates. Categorical variables were
included in the model and classiﬁed as 0 or 1 (for dichotomous
categories) and 0, 1 or 2 for those showing 3 categories. The B coefﬁcient
(B), R coefﬁcient (R) and R square (R squ) of the ﬁnal model that better
explained the overall QOLIE-31 score and the subscale domains were de-
termined. We did not adjust for multiple tests in order to avoid a type II
error [26], and a “p” level lower than 0.05was considered signiﬁcant. Var-
iables with clinical plausibility showing an association with a “p” level of
signiﬁcance lower than 0.10 were maintained in the ﬁnal model. The
analysiswas donewith the software package SPSS 17.0 (Chicago, IL, USA).
3. Results
Table 1 shows the correlations between the QOLIE-31 (overall score
and its subscale domains) and the clinical, demographic, radiologic, and
Table 1
Associations among the QOLIE-31 overall score or subscale domains seizure worry, overall QOL, emotional well-being and the clinical, demographic, radiologic, and psychiatric vari-
ables of the patients with refractory MTLE-HS.
Variables Overall score median
(IQ 25–75)
“p” level Seizure worry median
(IQ 25–75)
“p” level Overall QOL median
(IQ 25–75)
“p” leveld Emotional well-being
median (IQ 25–75)
“p” level
All patients 40.8 (25.1–52.3) N.A. 9 (0–31) N.A. 60 (50–77.5) N.A. 52 (32–66) N.A.
Sex
Male (n=35) 41.8 (34.1–52.5) 0.19 14 (0–39.3) 0.67 60 (47.5–73.8) 0.39 48 (28–64) 0.06
Female (n=46) 37.4 (22.4–52.5) 5 (0–25) 60 (50–77.5) 56 (40–72)
Marital status
Single (n=46) 42.6 (23.7–51.7) 0.89 12 (0–24.3) 0.67 60 (49.4–73.8) 0.69 54 (36–65) 0.60
Married (n=35) 39.7 (26.1–53.8) 9 (0–48) 60 (50–77.5) 48 (28–68)
Work activity
Yes (n=50) 40.6 (25.2–55.3) 0.45 14.5 (0–44.8) 0.08 60 (50–77.5) 0.95 52 (28–65) 0.59
No (n=31) 41.6 (25–50.1) 4 (0–24) 62.5 (47.5–77.5) 52 (40–68)
History of IPIa
No (n=23) 52.1 (25.4–60.8) 0.08 20 (0–51) 0.34 60 (50–77.5) 0.47 60 (40–72) 0.03
Yes (n=52) 40.1 (25–49.4) 9.5 (0–27) 60 (48.1–72.5) 42 (28–60)
Family history of epilepsy
No (n=65) 41.8 (25.8–54.3) 0.08 5 (0–28.5) 0.21 60 (50–77.5) 0.87 52 (36–66) 0.29
Yes (n=15) 36.8 (19.1–46.4) 20 (4–60) 60 (45–77.5) 40 (28–60)
MRI sideb
Right (n=36) 42.2 (25.8–53.7) 0.61 15.5 (0–46.3) 0.58 65 (47.5–77.5) 0.66 58 (28–72) 0.72
Left (n=39) 40.4 (22.7–52.1) 5 (0–39) 60 (50–77.5) 52 (36–60)
Bilateral (n=6) 35.1 (23.8–42.9) 6.5 (0–21.3) 51.3 (45.6–66.9) 40 (34–53)
Anxiety disorders
No (n=64) 42.7 (25.5–53.1) 0.45 9 (0–39) 0.71 60 (50–77.5) 0.30 52 (32–71) 0.30
Yes (n=17) 36.9 (25–51.5) 9 (0–27.5) 60 (45–71.3) 44 (32–58)
Depressive disorders
No (n=65) 44.6 (28.6–52.6) 0.07 5 (0–24) 0.75 65 (50–77.5) 0.03 56 (40–72) 0.003
Yes (n=16) 36.5 (20.4–50.1) 14.5 (0–39) 56.3 (43.8–63.1) 40 (20–60)
Axis II diagnosisc
No (n=63) 45.5 (28.2–54.3) 0.02 9 (0–27) 0.49 62.5 (50–77.5) 0.05 56 (36–72) 0.01
Yes (n=18) 28.9 (19.5–41.8) 14.5 (0–44.3) 50 (43.8–65) 40 (26–50)
AEDs
Monotherapy (n=11) 40.3 (15.9–67.8) 0.52 9 (0–61) 0.7 50 (24–60) 0.02 48 (28–72) 0.91
Monotherapy plus BDZ (n=24) 46.7 (29.8–55.7) 7.5 (0–37.5) 65 (50–77.5) 54 (36–71)
Polytherapy (n=46) 39.7 (24.8–50.2) 9 (0–25.5) 60 (50–73.8) 50 (28–64)
Pearson's correlation Pearson's correlation Pearson's correlation Pearson's correlation
Age, median (IQ range)
34 (28–44)years −0.42 0.0001 −0.11 0.35 −0.32 0.003 −0.37 0.001
Education level, median (IQ range)
8 (4–11)years −0.30 0.007 −0.15 0.18 −0.25 0.03 −0.27 0.02
Disease duration, median (IQ range)
23 (16–29)years −0.30 0.007 −0.12 0.27 −0.18 0.11 −0.35 0.002
Age of epilepsy onset, median (IQ range)
12 (6–16)years −0.18 0.11 −0.02 0.9 −0.21 0.06 −0.04 0.71
Seizures/month, median (IQ range)
4 (3–8) −0.21 0.06 −0.21 0.07 −0.17 0.14 −0.17 0.12
Associations among the QOLIE-31 subscale domains energy/fatigue, cognitive function, medication effects and social function and clinical, demographic, radiologic, and psychi-
atric variables of the patients with refractory MTLE-HS.
Variable Energy fatigue “p” leveld Cognitive function “p” level Medication effects “p” level Social function “p” level
All patients 55 (37.5–70) N.A. 41.1 (16.6–63.2) N.A. 33.3 (8.3–62.5) N.A. 17 (0–32.5) N.A.
Sex
Male (n=35) 50 (33.8–70) 0.06 39 (13.1–56.5) 0.22 33.3 (0–37) 0.3 16 (0–37)
Female (n=46) 60 (45–70) 46.6 (22.2–64.5) 41.7 (16.7–58.3) 17 (4–32) 0.77
Marital status
Single (n=46) 55 (40–70) 0.52 41 (16–63.1) 0.79 33.3 (6.2–58.3) 0.42 18 (0–33.8) 0.57
Married (n=35) 55 (35–70) 46.4 (17.5–63.6) 41.7 (8.3–75) 15 (4–28)
Work activity
Yes (n=50) 55 (35–70) 0.82 44.3 (16.6–66.1) 0.53 33.3 (0–52.1) 0.31 18 (0–32.3) 0.54
No (n=37) 55 (40–70) 40.8 (16.4–59.5) 41.7 (8.3–75) 41.6 (25–51)
History of IPIa
No (n=23) 70 (55–75) 0.004 48.3 (17.5–69.5) 0.39 33.3 (16.7–75) 0.32 22 (4–60) 0.05
Yes (n=52) 52.5 (35–60) 41 (13.5–62) 33.3 (0–58.3) 18 (0–31)
Family history
No (n=65) 55 (42.5–70) 0.18 46.4 (16.6–64.2) 0.11 33.3 (4.2–66.7) 0.50 15 (0–33) 0.47
Yes (n=15) 50 (30–70) 17.5 (7.5–57) 33.3 (8.3–50) 17 (4–24)
MRI sideb
Right (n=36) 52.5 (35–73.8) 0.75 41 (16.6–66.1) 0.52 29.2 (2.1–50) 0.1 16 (1–31) 0.51
Left (n=39) 55 (40–70) 42 (14–63) 41.7 (25–66.7) 17 (0–42)
Bilateralc (n=6) 52.5 (39–59) 39.6 (14–60.3) 25 (0–52.1) 16.5 (24–43)
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Variable Energy fatigue “p” leveld Cognitive function “p” level Medication effects “p” level Social function “p” level
Anxiety disorders
No (n=64) 55 (45–70) 0.004 41.4 (16.6–65.7) 0.47 33.3 (8.3–58.3) 0.94 16 (0–31) 0.42
Yes (n=17) 45 (25–57.5) 41.1 (13.3–53.5) 33.3 (0–70.8) 19 (4–45.5)
Depressive disorders
No (n=55) 60 (50–75) 0.0001 42.2 (16.6–66.1) 0.21 33.3 (8.3–66.6) 0.86 21.6 (0–33) 0.93
Yes (n=26) 45 (24–56.3) 37.4 (6.2–52.1) 37.5 (6.2–52.1) 19 (0–26.3)
Axis II diagnosis
No (n=63) 55 (45–75) 0.001 42.2 (17.5–63.9) 0.05 33.3 (16.6–66.6) 0.19 20 (4–40) 0.01
Yes (n=18) 42.5 (27.5–55) 20.4 (3.33–60.3) 33.3 (0–50) 4 (0–19.3)
AEDs
Monotherapy (n=11) 60 (35–70) 0.75 50.6 (24.2–64.5) 0.96 50 (25–83.3) 0.97 24 (4–60) 0.25
Monotherapy plus BDZ (n=24) 55 (50–75) 45.3 (12.3–71) 45.8 (18.7–73) 18.5 (0–32.5)
Polytherapy (n=46) 50 (35–70) 39.6 (16.5–59.4) 33.3 (0–43.7) 13 (0–28.8)
Pearson's correlation Pearson's correlation Pearson's correlation Pearson's correlation
Age, median (IQ range)
34 (28–44)years −0.28 0.012 −0.35 0.001 −0.19 0.08 −0.13 0.26
Education, median (IQ range)
8 (4–11)years −0.09 0.42 −0.21 0.06 −0.07 0.55 −0.24 0.03
Disease duration, median (IQ range)
23 (16–29)years −0.19 0.08 −0.28 0.01 −0.15 0.19 −0.08 0.4
Age of epilepsy onset, median (IQ range)
12 (6–16)years −0.12 0.28 −0.11 0.33 −0.07 0.53 −0.07 0.54
Seizures/month, median (IQ range)
4 (3–8) −0.23 0.04 −0.07 0.53 −0.21 0.06 −0.19 0.08
a IPI history was unknown in 2 patients.
b The hippocampus sclerosis was bilateral and symmetric in 2 cases and asymmetric in four cases (worse atrophy in the right side in 2 patients and in the left side in other 2).
c Axis II diagnosis: no=absence of personality disorder and yes=presence of personality disorder.
d The “p” levels of signiﬁcance were determined by student “t” test, ANOVA or Pearson's correlation test.
Table 1 (continued)
Association among the QOLIE-31 subscale domains energy/fatigue, cognitive function, medication effects and social function and clinical, demographic, radiologic, and psychi-
atric variables of the patients with refractory MTLE-HS.
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score of the QOLIE-31 was negatively correlated linearly with age
(Pearson's correlation — 0.42, p=0.0001), education level (Pearson's
correlation — 0.30, p=0.007) and disease duration (Pearson's correla-
tion— 0.30, p=0.007). Therewas a non-signiﬁcant trend for a negative
linear correlation between age of epilepsy onset (Pearson's correlation
— 0.18, p=0.11) and seizure frequency (Pearson's correlation — 0.21,
p=0.06). Each of the seven subscale domains of the QOLIE-31 showed
a variable linear correlation (R coefﬁcients range from 0.31 to 0.65)
among the predictive clinical, demographic, radiologic, and psychiatric
variables (see Table 1).
Table 2 shows the multiple linear regression that better explained
the independent associations among the overall QOLIE-31 score and
its subscale domains of the patients withMTLE, with the clinical, demo-
graphic, radiologic, and psychiatric variables. The regression model
showed that 36% of the overall score of the QOLIE-31 variance is
explained by history of IPI, family history of epilepsy, disease duration,
age of epilepsy onset, seizure frequency and axis II diagnosis. The
ﬁnal model including these variables showed a moderately strong
R coefﬁcient (0.66) for an independent negative linear relationship
with the overall QOLIE-31 score. When the subscale domains were
investigated, the ﬁnal model of the linear regression analysis showed
a moderately strong linear correlation for emotional well-being (R
coefﬁcient=0.61) and energy/fatigue (R coefﬁcient=0.65). The re-
gression models showed a fair linear correlation between the variables
retained in the models and seizure worry (R coefﬁcient=0.31), overall
QOL (R coefﬁcient=0.43), cognitive function (R coefﬁcient=0.39),
medication effects (R coefﬁcient=0.30) and social function (R co-
efﬁcient=0.42).
The variance of the QOLIE-31 subscales explained by their respective
regression models was: 7% for seizure worry (R coefﬁcient=0.31), 11%
for overall QOL (R coefﬁcient=0.43), 32% for emotional well-being
(R coefﬁcient=0.61), 38% for energy/fatigue (R coefﬁcient=0.65),
13% for cognitive function (R coefﬁcient=0.39), 7% for medicationeffects (R coefﬁcient=0.30), and 13% for social function (R coefﬁ-
cient=0.42) (see Table 2).
4. Discussion
We have demonstrated a moderately strong negative linear correla-
tion between history of IPI, family history of epilepsy in ﬁrst‐degree
relatives, disease duration, age of epilepsy onset, seizure frequency, per-
sonality disorder and the HRQoL of patients with refractory MTLE-HS.
Together, these variables can explain only 36% of the overall QOLIE-31
score variance, suggesting that other non-investigated variables may
be associated or may have contributed to the HRQoL in this speciﬁc
subset of patients. Furthermore, when the subscale domains of the
QOLIE-31 are analyzed, the combination of the investigated variables
predicted lower than 15% of the score variance in 5 of 7 subscale do-
mains investigated.
Our inclusion criteria were restricted to refractory MTLE-HS; how-
ever, there are evident similarities among our ﬁndings and those ob-
served in patients with other types of epilepsy. In our sample, as in
Taylor et al. [4], age, gender and marital status were not independently
associated with HRQoL determined by QOLIE-31 overall score or its
subscale domains.
Seizure frequency, the most commonly reported predictor of neg-
ative HRQoL [4], also showed a negative impact on the QOLIE-31
overall score in our patients. Disease duration and age of epilepsy
onset were also negatively associated with the QOLIE-31 overall
score in our patients, but these ﬁndings have been demonstrated to
be inconsistent in the literature [4].
The importance of medication use in HRQoL is also not clearly
established in the literature [4], and we did not ﬁnd associations be-
tween the overall score of the QOLIE-31 as well as the subscale domain
medication effects and the number of AEDs. It is noteworthy, however,
to consider that all patients were taking high doses of AEDs, even in
monotherapy.
Table 2
Multiple linear regression analysis showing the independent association between the
clinical, demographic, radiological and psychiatric variables and the overall QOLIE-31
score and its subscale domains of patients with MTLE.
QOLIE-31 R coefﬁcient Adjusted
R square
B coefﬁcient “p” level
Overall score 0.66 0.36
History of IPI −12.1 0.003
Family history of epilepsy −7.8 0.06
Disease duration −0.8 b0.0001
Age of epilepsy onset −0.9 b0.0001
Seizure frequency −0.7 0.006
Axis II diagnosis −4.4 0.04
Seizure worry 0.31 0.07
Work activity −12.1 0.04
Seizure frequency 0.8 0.03
Overall QOL 0.43 0.11
Axis II −9.2 0.07
Disease duration −0.52 0.02
Age of epilepsy onset −0.75 0.09
Seizure Frequency −0.54 0.05
Emotional well-being 0.61 0.32
History of IPI −13.7 0.004
Axis II diagnosis −9.4 0.05
Age −0.74 b0.0001
Seizure frequency −0.65 0.02
Depressive disorder −8.5 0.05
Energy/fatigue 0.65 0.38
History of IPI −16.8 0.001
Axis II diagnosis −14.9 0.002
Age −0.6 0.004
Seizure frequency −0.59 0.04
Depressive disorders −11.1 0.02
Cognitive function 0.39 0.13
Family history of epilepsy −12.6 0.08
Age −0.9 0.002
Medication effects 0.30 0.07
Age −0.6 0.05
Seizure frequency −0.9 0.03
Social function 0.42 0.13
Axis II diagnosis −14.5 0.03
Education −1.3 0.05
History of IPI −10.9 0.04
212 C. Pauli et al. / Epilepsy & Behavior 25 (2012) 208–213Still considering the QOLIE-31 overall score, we identiﬁed a relative-
ly strong independent negative association (B coefﬁcient:−12.1) with
positive history of IPI. Initial precipitant injury was clearly documented
in 65% of the patients; mean age of 4.7 (±2.5)years (data not shown).
The IPI predicted the QOLIE-31 through its negative inﬂuence on
emotional-well being, energy/fatigue and social function sub-scales.
We are not able to explain this association but considering the relatively
high level of signiﬁcance and its association with 3 subscales of
QOLIE-31 domains, we believe that the possibility of type I error is min-
imized, although not completely excluded.
The family history (ﬁrst degree) of epilepsy and presence of per-
sonality disorder also predicted negatively the QOLIE-31 overall
score, but their B coefﬁcient were respectively −7.8 and −4.4 in
comparison to that observed for the history of IPI occurrence. Both
these variables may have an important psychosocial impact on the
patient's life. In fact, in our clinical practice, patients became sad
when they inadvertently watch themselves having an epileptic
seizure in a video recorded by their family. We speculate that
living with a close relative who also has epilepsy might change the
patient's perception regarding the disease.
The individual analysis of QOLIE-31 subscales demonstrated the
speciﬁcity and weight of each investigated variable to predict each
HRQoL domain. We cannot exclude that some of the observed asso-
ciation may result by chance due to multiple comparisons [26];
however, the use of a more stringent level of signiﬁcance should
minimize the type I error. The possibility of a confounding bias dueto a co-segregation of another non-controlled variable also cannot
be excluded completely. Although the search for a biological plausi-
bility for an observed association may help to minimize the occurrence
of confounding bias, this is not an easy task for a complex variable like
HRQoL.
Cultural differences may also explain some particularities in HRQoL
and probably the literature conﬂicts. We compared the QOLIE-31
results of patients with refractory MTLE-HS from the Epilepsy Section
of Escola Paulista de Medicina (São Paulo Group) [1]. The QOLIE-31
subscale results were almost similar in both groups except for the
seizure worry subscale which was four times lower in our patients,
suggesting a clear difference in the seizure worry between the two
Brazilian samples of refractory MTLE-HS.
Psychiatric symptoms and psychological state may inﬂuence the
HRQoL of patients with non-neurological [27,28] and neurological
[29–31] chronic diseases, including epilepsy [3,8]. In the present work,
the occurrence of axis II PD was independently associated with a nega-
tive overall QOLIE-31 score aswell as the subscale domains overall QOL,
emotional well-being, energy/fatigue and social function. Although the
PD subtypes have not been described in detail in the Results, the most
common PD diagnosis was GGS (7 patients), histrionic (4), passive–
aggressive (2), avoidant (2), and borderline PD (1). The explanation
for the association between overall or subscale domains of QOLIE-31
and PD diagnosis remains unknown, probably, in part, due to the het-
erogeneity of PD symptoms. However, one common characteristic to
all the PD subtypes would be the presence of impaired functioning,
mainly in social activities. In traumatic brain injury survivors, we dem-
onstrated that HRQoL may be differently affected by the occurrence of
personality disorders [29]. The association between HRQoL and occur-
rence of personality disorders in patients with epilepsy deserves further
investigation. In the presentwork, the analysis of QOLIE-31 subscale do-
mains showed that depressive disorders were negatively associated
with emotional well-being and energy/fatigue in our patients. The
self-report of depressive symptoms in Beck Depression Inventory—II
(BDI-II) has been proved to be an independent predictor of HRQoL in
patients with refractory epilepsy. Interestingly, the BDI-II remains inde-
pendently associatedwith lower QOLIE-31 scores even in the sub-group
of patients without depressive symptoms (BDI-II scoreb10) [3,8], sug-
gesting the higher sensitivity of BDI-II to predict the QOLIE-31 than a
psychiatric diagnosis based on the SCID I. Among the 6 variables inde-
pendently associated with the QOLIE-31 in patients with refractory
MTLE‐HS, only seizure frequency is potentially treatable, and surgery
has been demonstrated to be effective in an observational, randomized
study [12].
The main positive aspects of our study are: i) the consecutive pa-
tient selection; ii) the well-deﬁned population; iii) multivariate data
analysis; iv) a detailed psychiatric diagnosis concurrent with the
HRQoL determination. The reader should be aware of the following
limitations: i) the relatively small sample size that may result in low
statistical power; ii) adequate sample size that was not calculated;
iii) the covariates that were not included on the basis of their theoret-
ical confounding or prognostic inﬂuence [2]; iv) all patients were
recruited from only one epilepsy center.
In summary, the variables commonly assessed in pre-surgical evalu-
ation of refractory MTLE-HS are limited to predict the HRQoL deter-
mined by QOLIE-31 overall score. The limitations became more
evident when these variables were used to predict QOLIE-31 subscale
domains. Identiﬁcation of other variables determining the HRQoL may
be important for epilepsy surgery decision-making and post-operative
follow-up of patients with refractory MTLE-HS.
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